Pfizer Inc.
Explore Pfizer
Core profile pages, annual revenue records, and related research hubs for this company.
Pfizer Inc.
Explore Pfizer
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$62.58B
Market Cap
$148.0B
Net Income
$7.8B
Employees
75,000
Pfizer reported $62.579 billion of FY2025 revenue, compared with $63.627 billion in FY2024 and $59.553 billion in FY2023. Net income was $7.771 billion in FY2025. Pfizer employed approximately 75,000 people worldwide as of December 31, 2025.
Revenue Trend Analysis
YoY Change
-1.6%
5-Year CAGR
+8.5%
Peak Year
2022
Trend
Mostly Growing
Pfizer Inc. has reported revenue across 6 fiscal years, compounding at +8.5% annually over 5 years. The most recent year saw a 1.6% decline versus the prior year. Revenue peaked in 2022 at $101.2B. Out of 5 reported periods, 3 showed growth and 2 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $62.6B | $7.8B | -1.6% |
| FY2024 | $63.6B | $8.0B | +6.8% |
| FY2023 | $59.6B | $2.1B | -41.1% |
| FY2022 | $101.2B | $31.4B | +24.5% |
| FY2021 | $81.3B | $22.0B | +95.2% |
| FY2020 | $41.7B | $9.2B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
It is highly volatile. In 2022 (the peak of the pandemic), revenue hit an astronomical $100 billion. By 2024, as demand for COVID vaccines evaporated, revenue plummeted back down to roughly $55 billion to $60 billion, causing severe panic on Wall Street.
The 'COVID Cliff.' Investors realized that the massive billions generated by the vaccine (Comirnaty) and the antiviral pill (Paxlovid) were a one-time windfall, not recurring revenue. Furthermore, Wall Street grew terrified that Pfizer did not have enough new drugs in its pipeline to replace upcoming patent expirations.
Massive acquisitions. CEO Albert Bourla took the unprecedented billions generated during the pandemic and aggressively bought several massive biotech companies, most notably acquiring Seagen for $43 billion to instantly dominate the oncology (cancer) market.
Historically, yes. Pfizer is heavily owned by retail investors because it pays a very high, highly reliable dividend yield. However, as revenue crashed post-COVID, some analysts expressed concern about whether the massive dividend was sustainable long-term without new blockbuster drugs.
Through massive cash flow. Despite the revenue crash, the core pharmaceutical business still generates tens of billions in operating cash flow, allowing Pfizer to service the massive debt they took on to acquire Seagen without immediately risking bankruptcy.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Pfizer Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/pfizer/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Pfizer Inc. reported $63B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/pfizer/financials" target="_blank" rel="noopener">CorpDigest — Pfizer Inc. financials</a></div>